Arbutus Biopharma Corp
Fermé
4.25 -1.85
Résumé
Variation du prix de l'action
24h
Min
4.17
Max
4.33
Revenu | 4M -3.8M |
|---|---|
Ventes | 522K 1.1M |
BPA | -0.014 |
Marge bénéficiaire | -357.374 |
Employés | 19 |
EBITDA | 75K -7.6M |
Prochains Résultats | 5 août 2026 |
|---|
Capitalisation Boursière | 26M 865M |
|---|---|
Ouverture précédente | 6.1 |
Clôture précédente | 4.25 |
Score Technique
By Trading Central
Confiance
Weak Bearish Evidence
Arbutus Biopharma Corp Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
Arbutus Biopharma Corp prévision
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
